Why the study?
Despite existing options for combined antihypertensive and lipid-lowering drugs, treating patients at high risk of cardiovascular events remains challenging in clinical practice.
Does a fixed-dose combination of lisinopril, amlodipine, and rosuvastatin improve efficacy and safety in comorbid patients with a high risk of cardiovascular events?
Does a fixed-dose combination of lisinopril, amlodipine, and rosuvastatin improve efficacy and safety in comorbid patients with a high risk of cardiovascular events?
A fixed-dose combination of lisinopril, amlodipine, and rosuvastatin may offer a personalized approach for managing comorbid patients at high cardiovascular risk.
May support personalized use in high-risk comorbid patients; leaves open confirmation by dedicated RCTs.
Hypertension and dyslipidemia are key risk factors for cardiovascular disease. Despite the currently existing possibilities for the combined use of various classes of antihypertensive and lipid-lowering drugs, the problem of treating patients with a high risk of cardiovascular events has not lost its significance and its solution in a specific clinical situation often remains very difficult. The review analyzes current data on the efficacy and safety of the fixed-dose combination of lisinopril, amlodipine and rosuvastatin to solve the problem of a personalized approach in the treatment of comorbid patients with a high risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Подзолков et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: